FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891640101> ?p ?o ?g. }

• W2891640101 endingPage "7041" @default.
• W2891640101 startingPage "7041" @default.
• W2891640101 abstract "7041 Background: In vitro studies showed that ofatumumab (O), a type I human antibody that targets a different CD20 epitope compared to rituximab, induces more potent antibody-dependent and complement mediated cell death. We hypothesized that substituting rituximab with ofatumumab, as part of Hyper-CVAD (HCVAD) regimen, may further improve outcomes in pts with Philadelphia chromosome (Ph) negative CD20+ ALL. Methods: Pts received 4 cycles (cy) of HCVAD [cy 1, 3, 5, 7 consisted of cyclophosphamide, doxorubicin, vincristine, and dexamethasone] alternating with 4 cy of methotrexate-cytarabine (MTX-ara-C, even cy 2, 4, 6, 8). Ofatumumab was infused on day 1 and 11 of cy 1 and 3; and day 1 and 8 of cy 2 and 4. For maintenance, pts received POMP, and late intensification with MTX/PEGylated asparaginase and O-HCVAD. Intrathecal MTX-Ara-C was used for CNS prophylaxis. Minimal residual disease (MRD) was assessed using multiparameter flow cytometry. Results: A total of 68 pts were enrolled (Table) and 65 were evaluable for response. Sixty-four pts (98%) achieved CR/CRp, 39/62 (63%) achieved negative MRD at time of CR, and 62/67 pts (93%) achieved negative MRD overall. Time to negative MRD was median 0.7 mo (range, 0.4-7.8). Pts received one to eight (median: 8) cy of intensive phase chemotherapy. The most common non-hematologic grade 3/4 toxicitiy was infection; occurred in 37 (56%) and 55 (81%) pts during induction and consolidation, respectively. At median 27 mo of follow-up (range 4-73), 51 pts (75%) are alive; 17 pts (25%) are receiving maintenance, 15 pts (22%) have relapsed, 14 pts (21%) have completed maintenance, and 12 pts (18%) have received ASCT in CR1. The 2-year CRD and OS were 79% and 81%, respectively. The 2-yr OS was 80% in both pts with <20% and ≥20% CD20 expression. Conclusions: O-HCAVD is highly effective and safe combination regimen in pts with CD20+ Ph-negative ALL. Clinical trial information: NCT01363128.Clinical Characteristics (n=68) N (%)/ Median [Range] Age, years 41 [18-71] ECOG PS > 1 7 (11) CNS disease 2 (3) CRFL2+ 8/34 (24) TP53+ 10/42 (24) CD20 expression > 20 % 42 (62) 10-20 % 7 (10) 1-10 % 19 (28) Cytogenetics Diploid 24 (35) Low hypodiploidy/near-triploidy 6 (9) High hyperdiploidy 5 (7) Complex 3 (5) Misc. 30 (44)" @default.
• W2891640101 created "2018-09-27" @default.
• W2891640101 creator A5000750846 @default.
• W2891640101 creator A5004203354 @default.
• W2891640101 creator A5011548707 @default.
• W2891640101 creator A5015101485 @default.
• W2891640101 creator A5020340537 @default.
• W2891640101 creator A5021380291 @default.
• W2891640101 creator A5022647201 @default.
• W2891640101 creator A5029750735 @default.
• W2891640101 creator A5038307470 @default.
• W2891640101 creator A5049173793 @default.
• W2891640101 creator A5050041791 @default.
• W2891640101 creator A5059600583 @default.
• W2891640101 creator A5061026876 @default.
• W2891640101 creator A5066354077 @default.
• W2891640101 creator A5074329862 @default.
• W2891640101 creator A5085521139 @default.
• W2891640101 creator A5090435894 @default.
• W2891640101 creator A5091492845 @default.
• W2891640101 date "2018-05-20" @default.
• W2891640101 modified "2023-10-18" @default.
• W2891640101 title "A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results." @default.
• W2891640101 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.7041" @default.
• W2891640101 hasPublicationYear "2018" @default.
• W2891640101 type Work @default.
• W2891640101 sameAs 2891640101 @default.
• W2891640101 citedByCount "12" @default.
• W2891640101 countsByYear W28916401012019 @default.
• W2891640101 countsByYear W28916401012020 @default.
• W2891640101 countsByYear W28916401012022 @default.
• W2891640101 crossrefType "journal-article" @default.
• W2891640101 hasAuthorship W2891640101A5000750846 @default.
• W2891640101 hasAuthorship W2891640101A5004203354 @default.
• W2891640101 hasAuthorship W2891640101A5011548707 @default.
• W2891640101 hasAuthorship W2891640101A5015101485 @default.
• W2891640101 hasAuthorship W2891640101A5020340537 @default.
• W2891640101 hasAuthorship W2891640101A5021380291 @default.
• W2891640101 hasAuthorship W2891640101A5022647201 @default.
• W2891640101 hasAuthorship W2891640101A5029750735 @default.
• W2891640101 hasAuthorship W2891640101A5038307470 @default.
• W2891640101 hasAuthorship W2891640101A5049173793 @default.
• W2891640101 hasAuthorship W2891640101A5050041791 @default.
• W2891640101 hasAuthorship W2891640101A5059600583 @default.
• W2891640101 hasAuthorship W2891640101A5061026876 @default.
• W2891640101 hasAuthorship W2891640101A5066354077 @default.
• W2891640101 hasAuthorship W2891640101A5074329862 @default.
• W2891640101 hasAuthorship W2891640101A5085521139 @default.
• W2891640101 hasAuthorship W2891640101A5090435894 @default.
• W2891640101 hasAuthorship W2891640101A5091492845 @default.
• W2891640101 hasConcept C126322002 @default.
• W2891640101 hasConcept C141071460 @default.
• W2891640101 hasConcept C143998085 @default.
• W2891640101 hasConcept C2776694085 @default.
• W2891640101 hasConcept C2776755627 @default.
• W2891640101 hasConcept C2777063308 @default.
• W2891640101 hasConcept C2778041864 @default.
• W2891640101 hasConcept C2778461978 @default.
• W2891640101 hasConcept C2778714382 @default.
• W2891640101 hasConcept C2778850193 @default.
• W2891640101 hasConcept C2779338263 @default.
• W2891640101 hasConcept C2779823535 @default.
• W2891640101 hasConcept C2780653079 @default.
• W2891640101 hasConcept C2781413609 @default.
• W2891640101 hasConcept C71924100 @default.
• W2891640101 hasConcept C90924648 @default.
• W2891640101 hasConceptScore W2891640101C126322002 @default.
• W2891640101 hasConceptScore W2891640101C141071460 @default.
• W2891640101 hasConceptScore W2891640101C143998085 @default.
• W2891640101 hasConceptScore W2891640101C2776694085 @default.
• W2891640101 hasConceptScore W2891640101C2776755627 @default.
• W2891640101 hasConceptScore W2891640101C2777063308 @default.
• W2891640101 hasConceptScore W2891640101C2778041864 @default.
• W2891640101 hasConceptScore W2891640101C2778461978 @default.
• W2891640101 hasConceptScore W2891640101C2778714382 @default.
• W2891640101 hasConceptScore W2891640101C2778850193 @default.
• W2891640101 hasConceptScore W2891640101C2779338263 @default.
• W2891640101 hasConceptScore W2891640101C2779823535 @default.
• W2891640101 hasConceptScore W2891640101C2780653079 @default.
• W2891640101 hasConceptScore W2891640101C2781413609 @default.
• W2891640101 hasConceptScore W2891640101C71924100 @default.
• W2891640101 hasConceptScore W2891640101C90924648 @default.
• W2891640101 hasIssue "15_suppl" @default.
• W2891640101 hasLocation W28916401011 @default.
• W2891640101 hasOpenAccess W2891640101 @default.
• W2891640101 hasPrimaryLocation W28916401011 @default.
• W2891640101 hasRelatedWork W1196768483 @default.
• W2891640101 hasRelatedWork W1519967065 @default.
• W2891640101 hasRelatedWork W2020898191 @default.
• W2891640101 hasRelatedWork W2134646407 @default.
• W2891640101 hasRelatedWork W2332362313 @default.
• W2891640101 hasRelatedWork W2362661449 @default.
• W2891640101 hasRelatedWork W2409484189 @default.
• W2891640101 hasRelatedWork W2994322074 @default.
• W2891640101 hasRelatedWork W3048802245 @default.
• W2891640101 hasRelatedWork W64123703 @default.
• W2891640101 hasVolume "36" @default.
• W2891640101 isParatext "false" @default.

• next